Go to main content | Go to main menu | Go to search

Project information
Gut OncoMicrobiome Signatures (GOMS) associated with cancer incidence, prognosis and prediction of treatment response (ONCOBIOME)

Information

This project doesn't include Faculty of Medicine. It includes Faculty of Science. Official project website can be found on muni.cz.
Investor logo
Project Identification
825410
Project Period
1/2019 - 6/2025
Investor / Pogramme / Project type
European Union
  • Horizon 2020
  • Health, demographic change and wellbeing (Societal Challenges)
MU Faculty or unit
Faculty of Science
Cooperating Organization
Masaryk Memorial Cancer Institute Brno
Ludwig-Maximilians-Universität München
University of Cambridge
Philipps-Universität Marburg
Universita degli Studi di Trento
Karolinska Institutet
Institut national de la santé et de la recherche médicale
Charité - Universitätsmedizin Berlin
INSTITUT GUSTAVE ROUSSY
  • Responsible person Prof. Laurence Zitvogel
Universitätsklinikum Erlangen
Radboud University Medical Center
EverImmune
Fondazione IRCCS Istituto Nazionale dei Tumori
Italian Institute for Genomic Medicine
UNICANCER
GBG Forschungs GmbH
Stichting Radboud universitair medisch centrum

Beyond its role in regulating multiple physiological functions that impact health, the intestinal metagenome is implicated in cancer initiation, progression and responses to therapies, even for extraintestinal neoplasia. Hence, there is an urgent need to fully identify and functionally characterize minimalist commensal ecosystems relevant to cancer, with reliable and robust methods, to validate cancer-associated gut microbiome fingerprints of high clinical relevance, and to develop diagnosis tools that will become part of the oncological arsenal for the optimization and personalization of therapy. Based on retro-and pro-spective studies, with large discovery and validation cohorts enrolling >9,000 cancer patients across 10 countries, ancillary to ongoing innovative clinical trials or FDA/EMA approvals across 4 frequent cancer types, ONCOBIOME will pursue the following aims: 1/ identify and validate core or cancer-specific Gut OncoMicrobiome Signatures (GOMS) associated with cancer occurrence, prognosis, response to, or progression on, therapy (polychemotherapy, immune checkpoint inhibitors, dendritic cell vaccines) or adverse effects, 2/ decipher the functional relevance of these cancer-associated gut commensal ecosystems in the regulation of host metabolism, immunity and oncogenesis, 3/ integrate these GOMS with other oncology hallmarks (clinics, genomics, immunomics, metabolomics) 4/ design optimal companion tests, based on those integrated signatures to predict cancer occurrence and progression. With high carat interdisciplinary experts, ONCOBIOME expects to validate cancer or therapy-specific Gut OncoMicrobiome Signatures (GOMS) across breast, colorectal, melanoma and lung cancers adjusting for covariates, to unravel the mode of action of these GOMS in innovative platforms, thus lending support to the design of cancer preventive campaigns using well characterized pre-and pro-biotics.

Sustainable Development Goals

Masaryk University is committed to the UN Sustainable Development Goals, which aim to improve the conditions and quality of life on our planet by 2030.

Sustainable Development Goal No. 3 – Good health and well-being Sustainable Development Goal No. 16 – Peace, justice and strong institutions Sustainable Development Goal No. 17 – Partnerships for the goals

Publications

Total number of publications: 5

2024

2023

2022

2021

You are running an old browser version. We recommend updating your browser to its latest version.

More info